This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne”.
The Board apologises to Mr Headley for the omission.
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne”.
The Board apologises to Mr Headley for the omission.
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne”.
The Board apologises to Mr Headley for the omission.
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne”.
The Board apologises to Mr Headley for the omission.
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne”.
The Board apologises to Mr Headley for the omission.
© 2021 Sensyne Health plc. All rights reserved.
Sensyne Health Group Limited. registered in England and Wales No. 11240986 is a trading company of Sensyne Health plc registered in England and Wales No. 11425451
Registered office: Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE, United Kingdom.
Note: Not all Sensyne Health products are available in all territories, for further information contact head office.
In support of the ‘Understanding Patient Data’ initiative, Sensyne Health cite that its “work uses data provided by patients and collected by the NHS as part of their care and support”. #datasaveslives
